Brevan Howard Capital Management’s Haemonetics HAE Stock Holding History

Brevan Howard Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.04M	Buy	18,488 +3,251	+21%	+$212K	0.01%	875
2025 Q4	$1.22M	Sell	15,237 -29,310	-66%	-$1.97M	0.01%	676
2025 Q3	$2.17M	Buy	44,547 +26,062	+141%	+$1.61M	0.01%	519
2025 Q2	$1.38M	Sell	18,485 -6,157	-25%	-$408K	0.01%	914
2025 Q1	$1.57M	Sell	24,642 -168	-0.7%	-$11.4K	0.02%	361
2024 Q4	$1.94M	Buy	24,810 +19,890	+404%	+$1.6M	0.01%	290
2024 Q3	$395K	Buy	4,920 +1,111	+29%	+$89.8K	﹤0.01%	758
2024 Q2	$315K	Buy	+3,809	New	+$335K	﹤0.01%	761

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brevan Howard Capital Management's HAE Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Haemonetics (HAE) stake by 21% in Q1 2026, buying an estimated $212K and bringing the position to 18,488 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #875.

Brevan Howard Capital Management first reported a position in HAE in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.17M in Q3 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

Brevan Howard Capital Management held 18,488 shares of Haemonetics worth $1.04M as of Q1 2026.
Brevan Howard Capital Management bought 3,251 Haemonetics shares in Q1 2026, an estimated $212K.
Haemonetics made up 0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #875 holding.
Brevan Howard Capital Management first reported a position in Haemonetics in Q2 2024 and has held it in 8 quarters since.
Brevan Howard Capital Management's Haemonetics position peaked at $2.17M in Q3 2025.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.